Gynecologic Oncology Research
Clinical trials are people-based studies — as opposed to animal or lab studies — of new drugs or procedures. Doctors use clinical trials to learn whether a new treatment is safe and effective in patients. Such studies are vital to the development of new treatments for diseases such as cancer.
The Division of Gynecologic Oncology is a member and active participant in the Gynecologic Oncology Group (GOG), a National Cancer Institute (NCI)-sponsored clinical-trials organization that offers the latest in clinical-trials organization that offers the latest in clinical research trials for gynecologic oncology patients. GOG is the only group which focuses its research on women with cancer of the ovary, uterus, and cervix. The Division is also a participant of industry-sponsored studies.
- Epidemiology of leiomyosarcoma and other smooth muscle tumors of uncertain malignant potential in an inner city population
- GOG #210: A Molecular Staging Study of Endometrial Carcinoma
- GOG #218: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or XYOTAX (CT-2103) (IND#70177), No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy